“Semaglutide and tirzepatide are often lumped together under the umbrella of GLP-1 drugs, but they differ in one key regard: tirzepatide mimics not only GLP-1 but also a complementary hormone called gastric inhibitory polypeptide (GIP). This hormone further revs up energy metabolism and affects how the body stores and burns nutrients. Tirzepatide’s dual action is thought to contribute to its superior weight-loss results.
In a large head-to-head trial, sponsored by tirzepatide’s maker Eli Lilly in Indianapolis, Indiana, participants who took tirzepatide lost an average of 20% of their body weight, outpacing the 14% reduction achieved with semaglutide…
Inspired by tirzepatide’s success, many companies are advancing other drugs that engage GLP-1 and GIP receptors. At least five tirzepatide-like therapies are progressing through clinical trials, with the first expected to hit the market by 2028.”
From Nature.